Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Momelotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 20/20 | 1.00 |
| ▸ | JAK1 known ✓ | P23458 | 10/20 | 1.00 |
| ▸ | ACVR1 known ✓ | Q04771 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 16/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 3/20 | 1.00 |
| ▸ | TYK2 | P29597 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | OPA1 | O60313 | 1/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 1.00 |
| ▸ | STK16 | O75716 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | MARK3 | P27448 | 1/20 | 1.00 |
| ▸ | BMPR1A | P36894 | 1/20 | 1.00 |
| ▸ | TGFBR1 | P36897 | 1/20 | 1.00 |
| ▸ | STAT3 | P40763 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Momelotinib SCHEMBL22282523 | 1.00 | JAK2 (1.00) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL29352115 | 1.00 | JAK2 (1.00) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL2863022 | 0.99 | JAK2 (0.98) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL29774318 | 0.99 | JAK2 (0.98) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL17333087 | 0.99 | JAK2 (0.98) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL2863013 | 0.99 | JAK2 (0.98) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL3619656 | 0.97 | JAK2 (0.93) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL30051896 | 0.97 | JAK2 (0.93) | JAK2JAK3JAK1HDAC1TYK2 | |
| Momelotinib SCHEMBL3619662 | 0.97 | JAK2 (0.93) | JAK2JAK3JAK1HDAC1TYK2 | |
| SCHEMBL2858799 | 0.94 | JAK2 (0.89) | JAK2JAK3JAK1HDAC1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 601 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026043077-A1 | MIXED STRAINS FOR ALLEVIATING SARCOPENIA AND COMPOSITION COMPRISING SAME | 주식회사 락토메이슨 | 2026-02-26 | — | — | WO | claimed |
| US-RE50497-E1 | (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide | GLAXOSMITHKLINE LLC (US) | 2025-07-22 | — | — | US | claimed |
| CN-119792300-A | Pharmaceutical composition for treating kidney cancer | 复旦大学附属肿瘤医院 | 2025-04-11 | — | — | CN | claimed |
| CN-118930560-A | Bifunctional degradation agents for hematopoietic progenitor cell kinases and therapeutic uses thereof | 新锐思生物制药股份有限公司 | 2024-11-12 | — | — | CN | claimed |
| EP-4430052-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | claimed |
| CN-118510786-A | Bifunctional degradation agents for hematopoietic progenitor cell kinases and therapeutic uses thereof | 新锐思生物制药股份有限公司 | 2024-08-16 | — | — | CN | claimed |
| EP-4412621-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT Bio Corp. (US) | 2024-08-14 | — | — | EP | claimed |
| CN-115605488-B | Bifunctional degradation agents for hematopoietic progenitor cell kinases and therapeutic uses thereof | 新锐思生物制药股份有限公司 | 2024-08-09 | — | — | CN | claimed |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | claimed |
| CN-113227089-B | Substituted 6-azabenzimidazole compounds as HPK1 inhibitors | 吉利德科学公司 | 2024-07-05 | — | — | CN | claimed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | claimed |
| US-20140005180-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2014-01-02 | — | — | US | claimed |
| EP-2646029-A1 | TREATMENT OF JAK2-MEDIATED CONDITIONS | YM BioSciences Australia Pty Ltd (AU) | 2013-10-09 | — | — | EP | claimed |
| WO-2013112942-A1 | BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION | DNA TRIX, INC. (US) | 2013-08-01 | — | — | WO | claimed |
| US-8486941-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-07-16 | — | — | US | claimed |
| WO-2012149602-A1 | MULTIPLE MYELOMA TREATMENT | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2012-11-08 | — | — | WO | claimed |
| WO-2012071612-A1 | TREATMENT OF JAK2-MEDIATED CONDITIONS | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2012-06-07 | — | — | WO | claimed |
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2010-08-05 | — | — | US | claimed |
| EP-2152701-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | Cytopia Research Pty Ltd (AU) | 2010-02-17 | — | — | EP | claimed |
| WO-2008109943-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD (AU) | 2008-09-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885ACVR1 3660/4885 |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | HIPK1, HPGDS, HIPK3 | JAK2 591/4885JAK1 556/4885ACVR1 2079/4885 |
| US-20140005180-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885ACVR1 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.